Alpha Centric Advisors LLC Biocryst Pharmaceuticals Inc Transaction History

Alpha Centric Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $129,480 - $176,020	26,000 Added 4.01%	675,000 $4.04 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $530,090 - $625,680	79,000 Added 13.86%	649,000 $4.59 Million
Q2 2023 Aug 08, 2023	BUY	$6.96 - $8.81 $1.05 Million - $1.33 Million	150,500 Added 35.88%	570,000 $4.01 Million
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $2.34 Million - $3.49 Million	294,500 Added 235.6%	419,500 $3.5 Million
Q4 2022 Feb 07, 2023	BUY	$10.5 - $14.2 $577,500 - $781,000	55,000 Added 78.57%	125,000 $1.44 Million
Q3 2022 Nov 08, 2022	BUY	$10.79 - $14.81 $566,475 - $777,525	52,500 Added 300.0%	70,000 $882,000
Q4 2021 Feb 25, 2022	BUY	$11.18 - $15.46 $195,650 - $270,550	17,500 New	17,500 $242,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.